Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2014

01-03-2014 | Research Article

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

Authors: R. Andrés, I. Pajares, J. Balmaña, G. Llort, T. Ramón y Cajal, I. Chirivella, E. Aguirre, L. Robles, E. Lastra, P. Pérez-Segura, N. Bosch, C. Yagüe, E. Lerma, J. Godino, M. D. Miramar, M. Moros, P. Astier, B. Saez, M. J. Vidal, A. Arcusa, S. Ramón y Cajal, M. T. Calvo, A. Tres

Published in: Clinical and Translational Oncology | Issue 3/2014

Login to get access

Abstract

Background

BRCA1-associated breast cancers have been associated to a triple-negative phenotype. The prevalence of BRCA1 germline mutations in young onset TNBC based on informativeness of family history has not been reported.

Patients and methods

From January 2008 to May 2009 were collected blood and tumor samples from patients with TNBC younger than 50 years and without a family history of breast and ovarian cancer in first- and second-degree relatives. Analysis of BRCA1 germline mutations was made. Age at diagnosis and informativeness of family history (presence of female in first- and second-degree relatives alive until age 45) was collected in all cases. Immunohistochemistry of basal-like features was performed centrally in all available tumors.

Results

Seven pathogenic mutations were detected in 92 patients (7.6 %), two of them in patients younger than 35 years (28.6 %) (Fisher’s exact test, p = 0.631). Three non-classified variants were detected (3.2 %). Family history was informative in two patients with a pathogenic mutation (28.6 %) and not informative in five (71.4 %) (Fisher’s exact test, p = 0.121). Of the seven patients with a pathogenic mutation, four had a basal-like phenotype.

Conclusion

Patients with apparently sporadic TNBC younger than 50 years and a non-informative family history are candidates for germline genetic testing of BRCA1.
Literature
1.
go back to reference Mavaddat N, Rebbeck TR, Lakhani SR, Eaton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010;12(3):R28.PubMedCentralPubMedCrossRef Mavaddat N, Rebbeck TR, Lakhani SR, Eaton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010;12(3):R28.PubMedCentralPubMedCrossRef
2.
go back to reference James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol. 2006;24(4):707–15.PubMedCrossRef James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol. 2006;24(4):707–15.PubMedCrossRef
3.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cáncer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.PubMedCentralPubMedCrossRef Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cáncer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.PubMedCentralPubMedCrossRef
4.
go back to reference Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, et al. Phenotypic characterization of BRCA1 y BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90(1):5–14.PubMedCrossRef Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, et al. Phenotypic characterization of BRCA1 y BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90(1):5–14.PubMedCrossRef
5.
go back to reference Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H, et al. Histopathological features of breast tumor in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(1):R93–100.PubMedCentralPubMedCrossRef Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H, et al. Histopathological features of breast tumor in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(1):R93–100.PubMedCentralPubMedCrossRef
6.
go back to reference Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germinale BRCA1 mutations and basal epithelial phenotype breast cancer. J Natl Cancer Inst. 2003;95(19):482–5.CrossRef Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germinale BRCA1 mutations and basal epithelial phenotype breast cancer. J Natl Cancer Inst. 2003;95(19):482–5.CrossRef
7.
go back to reference Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;14:5175–80.CrossRef Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;14:5175–80.CrossRef
8.
go back to reference Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1 and BRCA2 related breast cancer: the influence of age, grade and histological type. Clin Cancer Res. 2004;10(6):2029–34.PubMedCrossRef Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1 and BRCA2 related breast cancer: the influence of age, grade and histological type. Clin Cancer Res. 2004;10(6):2029–34.PubMedCrossRef
9.
go back to reference Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(4):R465–9.PubMedCentralPubMedCrossRef Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7(4):R465–9.PubMedCentralPubMedCrossRef
10.
go back to reference Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7(7):1937–45.PubMed Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001;7(7):1937–45.PubMed
11.
go back to reference Lidereau R, Eisinger F, Champeme MH, Budd GT, Darlington G, Myles J, et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000;60(5):1206–10.PubMed Lidereau R, Eisinger F, Champeme MH, Budd GT, Darlington G, Myles J, et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000;60(5):1206–10.PubMed
12.
go back to reference Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001;7(6):1739–41.PubMed Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001;7(6):1739–41.PubMed
13.
go back to reference Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;19(9):86.CrossRef Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;19(9):86.CrossRef
14.
go back to reference Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297:2587–95.PubMedCrossRef Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297:2587–95.PubMedCrossRef
15.
go back to reference Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 1994;8(4):392–8.PubMedCrossRef Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 1994;8(4):392–8.PubMedCrossRef
16.
go back to reference Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.PubMedCrossRef Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.PubMedCrossRef
17.
go back to reference Farshid G, Balleine RL, Cummings M, Waring P. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol. 2006;30(11):1357–66.PubMedCrossRef Farshid G, Balleine RL, Cummings M, Waring P. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol. 2006;30(11):1357–66.PubMedCrossRef
18.
go back to reference Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer. 1999;84(3):263–7.PubMedCrossRef Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer. 1999;84(3):263–7.PubMedCrossRef
19.
go back to reference Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 year. Br J Cancer. 2012;106:1234–8.PubMedCentralPubMedCrossRef Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 year. Br J Cancer. 2012;106:1234–8.PubMedCentralPubMedCrossRef
20.
go back to reference Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA Mutations in an Unselected Population of Triple-Negative Breast Cancer. Cancer. 2012;118(11):2787–95.PubMedCrossRef Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA Mutations in an Unselected Population of Triple-Negative Breast Cancer. Cancer. 2012;118(11):2787–95.PubMedCrossRef
21.
go back to reference Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214–20.PubMedCrossRef Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214–20.PubMedCrossRef
22.
go back to reference Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175–80.PubMedCrossRef Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175–80.PubMedCrossRef
23.
go back to reference Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg. 2009;33(7):1093–7. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg. 2009;33(7):1093–7.
Metadata
Title
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)
Authors
R. Andrés
I. Pajares
J. Balmaña
G. Llort
T. Ramón y Cajal
I. Chirivella
E. Aguirre
L. Robles
E. Lastra
P. Pérez-Segura
N. Bosch
C. Yagüe
E. Lerma
J. Godino
M. D. Miramar
M. Moros
P. Astier
B. Saez
M. J. Vidal
A. Arcusa
S. Ramón y Cajal
M. T. Calvo
A. Tres
Publication date
01-03-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1070-9

Other articles of this Issue 3/2014

Clinical and Translational Oncology 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine